CTO News Hubb
Advertisement
  • Home
  • CTO News
  • IT
  • Technology
  • Tech Topics
    • AI
    • QC
    • Robotics
    • Blockchain
  • Contact
No Result
View All Result
  • Home
  • CTO News
  • IT
  • Technology
  • Tech Topics
    • AI
    • QC
    • Robotics
    • Blockchain
  • Contact
No Result
View All Result
CTO News Hubb
No Result
View All Result
Home AI

Artificial intelligence could help clinicians assess which patients are likely to encounter the harmful side effects of some commonly used antidepressants, antihistamines and bladder medicines. — ScienceDaily

January 23, 2023
in AI


Research led by the University of Exeter and Kent and Medway NHS and Social Care Partnership Trust, published in Age and Ageing, assessed a new tool designed to calculate which medicines are more likely to experience adverse anticholinergic effects on the body and brain. These complications can occur from many -prescription and over-the-counter drugs which affects the brain by blocking a key neurotransmitter called acetylcholine. Many medicines, including some bladder medications, anti-depressants, medications for stomach and Parkinson’s disease have some degree of anticholinergic effect. They are commonly taken by older people.

Anticholinergic side effects include confusion, blurred vision, dizziness, falls and a decline in brain function. Anticholinergic effects may also increase risks of falls and may be associated with an increase in mortality. They have also been linked to a higher risk of dementia when used long term.

Now, researchers have developed a tool to calculate harmful effects of medicines using artificial intelligence. The team created a new online tool, International Anticholinergic Cognitive Burden Tool (IACT), is uses natural language processing which is an artificial intelligence methdolody and chemical structure analysis to identify medications that have anticholinergic effect.

The tool is the first to incorporate a machine learning technique, to develop an automatically updated tool available on a website portal. The anticholinergic burden is assessed by assigning a score based on reported adverse events and aligning closely with the chemical structure of the drug being considered for prescription, resulting in a more accurate and up-to-date scoring system than any previous system. Ultimately, after further research and modelling with real world patient data the tool developed could help to support prescribing reducing risks form common medicines.

Professor Chris Fox, at the University of Exeter, is one of the study authors. He said:: “Use of medicines with anticholinergic effects can have significant harmful effects for example falls and confusion which are avoidable, we urgently need to reduce the harmful side effects as this can leads to hospitalisation and death. This new tool provides a promising avenue towards a more tailored personalised medicine approach, of ensuring the right person gets a safe and effective treatment whilst avoiding unwanted anticholinergic effects.”

The team surveyed 110 health professionals, including pharmacists and prescribing nurses. Of this group, 85 per cent said they would use a tool to assess risk of anticholinergic side effects, if available. The team also gathered usability feedback to help improve the tool further.

Dr Saber Sami, at the University of East Anglia, said: “Our tool is the first to use innovative artificial intelligence technology in measures of anticholinergic burden — ultimately, once further research has been conducted the tool should support pharmacists and prescribing health professionals in finding the best treatment for patients.”

Professor Ian Maidment, from Aston University, said: “I have been working in this area for over 20 years. Anti-cholinergic side-effects can be very debilitating for patients. We need better ways to assess these side-effects.”

The research team includes collaboration with AKFA University Medical School, Uzbekistan, and the Universities of East Anglia, Aston, Kent and Aberdeen. They aim to continue development of the tool with the aim that it can be deployed in day-to-day practice which this study supports.



Source link

Tags: Personalized Medicine; Pharmacology; Colon Cancer; Intelligence; Marijuana; Disorders and Syndromes; Artificial Intelligence; Quantum Computers; Computers and Internet
Previous Post

Putting clear bounds on uncertainty | MIT News

Next Post

Cheap Phones Shouldn’t Exist – Review Geek

Next Post

Cheap Phones Shouldn’t Exist – Review Geek

Meta Eyes a Moderation Partner With ‘Traumatizing’ Working Conditions

Trending News

Spotlight Q&A with GitHub’s Jason Warner

November 1, 2022

Who Will Blockchain Put out of Business?

December 26, 2022

The Hard Truth About Performance — A Guide for CTOs

December 31, 2022

© 2022 CTO News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • CTO News
  • IT
  • Technology
  • AI
  • QC
  • Robotics
  • Blockchain
  • Contact

Newsletter Sign Up

No Result
View All Result
  • Home
  • CTO News
  • IT
  • Technology
  • Tech Topics
    • AI
    • QC
    • Robotics
    • Blockchain
  • Contact

© 2021 JNews – Premium WordPress news & magazine theme by Jegtheme.

SUBSCRIBE TO OUR WEEKLY NEWSLETTERS